Actualité

At Instituto Bernabeu, we are an innovative medical centre which applies the latest, cutting edge technologies and techniques to improve our patient's living standards.

Dr. Joaquin Llacer, associate director at Instituto Bernabeu, has been elected to represent all Spanish specialist doctors at the European Society of Human Reproduction and Embryology.

Everything is changing in order to ensure that all remains the same. That is, offering a personalised treatment to every patient attending Instituto Bernabeu.

A study by the Instituto Bernabeu selected by the committee of experts of the international meeting of the European Society of Human Reproduction and Embryology, held from 2 to 5 July in Geneva, finds a correlation between the manner in which embryo division takes place and the future chromosome count of the embryo. 

New issue of Instituto Bernabeu corporate newsletter (IB NEWSLETTER). Instituto Bernabeu leads the new research for the treatment of implantation failure of the embryo and its link with recurrent miscarriage. One of these lines of work is focused on the personalization of the treatment to the specific response of each patient.

Instituto Bernabeu has revolutionised the way in which drugs for ovarian stimulation are used. Three days' worth of medicine can be taken in a single injection thanks to a device known as the i-Port which is already being used by diabetics. During courses of fertility treatment and when ovarian stimulation lasting an average of ten days is carried out, drugs need to be administered using injections. Many of the women who come to our clinic admit to being afraid of needles.

The Instituto Bernabeu Group will travel to Switzerland where the reproductive medicine clinic will present eleven pieces of research work carried out by experts at the reproductive medicine clinic. The international scientific committee at the European Society of Human Reproduction and Embryology has selected the research that will be made public during the 33^rd edition of the annual congress to be held between 2^nd and 5^th July in Geneva.

Patients undergoing treatment in the egg donation programme and patients undergoing frozen embryo transfer need to be administered progesterone. It is necessary for implantation and for the posterior progress of the pregnancy. Drugs can be administered either by means of a daily subcutaneous injection or vaginally over a period of at least three months. Given that this is a significant period of time, Instituto Bernabeu believes that it is key that the female patient feels at ease if she is to have a good quality of life.

At the European Society of Human Reproduction and Embryology (ESHRE) congress, Instituto Bernabeu will present work on how genetics affects responses to drugs and how they can be used in order to improve ovarian stimulation in women with poor response. The reproductive medicine clinic has pioneered the use of drugs linked to genetics through IBgen and, on this occasion, has developed research work entitled 'A pharmacogenetic approach to improving low ovarian response with androgen pre-treatment'. It will be presented at the event to be held between 2^nd and 5^th July in Switzerland.

The Director of the Endocrinology and Nutrition Department at Instituto Bernabeu, Dr Pino Navarro, will participate as a speaker in the XXII edition of the Continuous Training Course on Endocrinology and Nutrition for internal resident doctors organised by the Spanish Endocrinology and Nutrition Society. Dr Navarro will give a practical workshop on endocrinology and fertility.